DOP2024000230A - Proteínas de fusión hmpv de prefusión estabilizadas - Google Patents
Proteínas de fusión hmpv de prefusión estabilizadasInfo
- Publication number
- DOP2024000230A DOP2024000230A DO2024000230A DO2024000230A DOP2024000230A DO P2024000230 A DOP2024000230 A DO P2024000230A DO 2024000230 A DO2024000230 A DO 2024000230A DO 2024000230 A DO2024000230 A DO 2024000230A DO P2024000230 A DOP2024000230 A DO P2024000230A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- fusion proteins
- hmpv
- stabilized prefusion
- hmpv fusion
- prefusion
- Prior art date
Links
- 241000342334 Human metapneumovirus Species 0.000 title 1
- 102000037865 fusion proteins Human genes 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 abstract 2
- 241000711902 Pneumovirus Species 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
- C12N2760/18322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
- C12N2760/18334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22173131 | 2022-05-12 | ||
| PCT/EP2023/062652 WO2023217988A1 (en) | 2022-05-12 | 2023-05-11 | Stabilized pre-fusion hmpv fusion proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2024000230A true DOP2024000230A (es) | 2025-02-16 |
Family
ID=81653543
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2024000230A DOP2024000230A (es) | 2022-05-12 | 2024-11-11 | Proteínas de fusión hmpv de prefusión estabilizadas |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP4522209A1 (enExample) |
| JP (1) | JP2025521082A (enExample) |
| KR (1) | KR20250010642A (enExample) |
| CN (1) | CN119562826A (enExample) |
| AU (1) | AU2023269241A1 (enExample) |
| CA (1) | CA3253332A1 (enExample) |
| CL (1) | CL2024003418A1 (enExample) |
| CO (1) | CO2024015386A2 (enExample) |
| CR (1) | CR20240493A (enExample) |
| DO (1) | DOP2024000230A (enExample) |
| GE (1) | GEAP202516650A (enExample) |
| IL (1) | IL316911A (enExample) |
| JO (1) | JOP20240256A1 (enExample) |
| MX (1) | MX2024013959A (enExample) |
| PE (1) | PE20251395A1 (enExample) |
| WO (1) | WO2023217988A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2026504862A (ja) | 2023-01-18 | 2026-02-10 | ファイザー・インク | 呼吸器疾患に対するワクチン |
| WO2025126071A1 (en) | 2023-12-14 | 2025-06-19 | Pfizer Inc. | Rna molecules |
| WO2025144636A1 (en) * | 2023-12-26 | 2025-07-03 | The Scripps Research Institute | ENGINEERED hMPV F PROTEIN IMMUNOGENS AND RELATED VACCINES |
| WO2025163460A2 (en) * | 2024-01-30 | 2025-08-07 | Pfizer Inc. | Vaccines against respiratory diseases |
| WO2026018181A1 (en) | 2024-07-17 | 2026-01-22 | Pfizer Inc. | Immunogenic compositions and uses thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3584341D1 (de) | 1984-08-24 | 1991-11-14 | Upjohn Co | Rekombinante dna-verbindungen und expression von polypeptiden wie tpa. |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| NZ230747A (en) | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
| WO1990014837A1 (en) | 1989-05-25 | 1990-12-13 | Chiron Corporation | Adjuvant formulation comprising a submicron oil droplet emulsion |
| US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
| AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| PL215165B1 (pl) | 2002-04-25 | 2013-10-31 | Crucell Holland Bv | Rekombinowany wektor adenowirusowy oraz sposób wytwarzania rekombinowanego wektora adenowirusowego |
| SE0202110D0 (sv) | 2002-07-05 | 2002-07-05 | Isconova Ab | Iscom preparation and use thereof |
| SE0301998D0 (sv) | 2003-07-07 | 2003-07-07 | Isconova Ab | Quil A fraction with low toxicity and use thereof |
| JP7382230B2 (ja) | 2016-10-17 | 2023-11-16 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | 組み換えウイルスレプリコン系及びその使用 |
| BR112019011661A2 (pt) | 2016-12-05 | 2020-01-07 | Synthetic Genomics, Inc. | Composições e métodos para aumentar expressão de gene |
| US12559544B2 (en) * | 2019-05-21 | 2026-02-24 | University Of Georgia Research Foundation, Inc. | Antibodies that bind human metapneumovirus fusion protein and their use |
| CN116615235A (zh) * | 2020-10-09 | 2023-08-18 | 得克萨斯州大学系统董事会 | 融合前稳定的hmpv f蛋白 |
-
2023
- 2023-05-11 GE GEAP202516650A patent/GEAP202516650A/en unknown
- 2023-05-11 CN CN202380053513.6A patent/CN119562826A/zh active Pending
- 2023-05-11 KR KR1020247040979A patent/KR20250010642A/ko active Pending
- 2023-05-11 JP JP2024566227A patent/JP2025521082A/ja active Pending
- 2023-05-11 IL IL316911A patent/IL316911A/en unknown
- 2023-05-11 CA CA3253332A patent/CA3253332A1/en active Pending
- 2023-05-11 CR CR20240493A patent/CR20240493A/es unknown
- 2023-05-11 WO PCT/EP2023/062652 patent/WO2023217988A1/en not_active Ceased
- 2023-05-11 PE PE2024002522A patent/PE20251395A1/es unknown
- 2023-05-11 AU AU2023269241A patent/AU2023269241A1/en active Pending
- 2023-05-11 EP EP23727473.3A patent/EP4522209A1/en active Pending
-
2024
- 2024-11-08 CL CL2024003418A patent/CL2024003418A1/es unknown
- 2024-11-11 MX MX2024013959A patent/MX2024013959A/es unknown
- 2024-11-11 JO JOJO/P/2024/0256A patent/JOP20240256A1/ar unknown
- 2024-11-11 DO DO2024000230A patent/DOP2024000230A/es unknown
- 2024-11-12 CO CONC2024/0015386A patent/CO2024015386A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3253332A1 (en) | 2023-11-16 |
| CL2024003418A1 (es) | 2025-08-01 |
| JOP20240256A1 (ar) | 2024-11-11 |
| AU2023269241A1 (en) | 2024-11-21 |
| WO2023217988A1 (en) | 2023-11-16 |
| IL316911A (en) | 2025-01-01 |
| MX2024013959A (es) | 2025-02-10 |
| CO2024015386A2 (es) | 2024-11-28 |
| GEAP202516650A (en) | 2025-03-10 |
| CN119562826A (zh) | 2025-03-04 |
| JP2025521082A (ja) | 2025-07-08 |
| KR20250010642A (ko) | 2025-01-21 |
| CR20240493A (es) | 2025-01-29 |
| PE20251395A1 (es) | 2025-05-22 |
| EP4522209A1 (en) | 2025-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2024015386A2 (es) | Proteínas de fusión de hmpv de prefusión estabilizadas | |
| CO2023005373A2 (es) | Proteínas f de hmpv estabilizadas por prefusión | |
| CO2021005987A2 (es) | Compuestos de anillo fusionado | |
| MX2022015272A (es) | Inhibidores de la proteina kras g12c y usos de estos. | |
| BR112012009289A2 (pt) | isolamento e purificação de anticorpos anti-il-13 com uso de cromatografia de afinidade com proteína a. | |
| AR113142A1 (es) | Moléculas de unión al antígeno multiespecíficas que tienen actividad de sustitución de la función de cofactor del factor viii de coagulación de sangre (fviii), y formulaciones farmacéuticas que contienen dicha molécula como ingrediente activo | |
| MX2020013977A (es) | Proteínas quiméricas transmembrana y usos de las mismas. | |
| SV2007002813A (es) | Compuestos para la modulacion de la actividad del c-fms y/o el c-kit y sus usos aplicables | |
| GT201000148A (es) | Anticuerpos antimesotelina y usos de los mismos | |
| GT200900268A (es) | Polipeptidos de factor vii modificados y usos de los mismos . | |
| MX2012008225A (es) | Formulaciones liquidas que contienen anticuerpo estabilizado. | |
| AR114565A1 (es) | Proteínas de fusión fc il-22 y métodos de uso | |
| BR112017013956B8 (pt) | Proteínas de fusão de citocinas | |
| DOP2017000191A (es) | Nuevas proteínas específicas para pioverdina y pioquelina | |
| BR112022022937A2 (pt) | Proteínas de fusão estabilizadas de proteína de pico de coronavírus | |
| CU20130063A7 (es) | Proceso de producción de depsipéptidos cíclicos | |
| BR112014019277A8 (pt) | Populações de células-tronco estromais, tecidos, métodos de isolamento de células-tronco estromais, método de obtenção de tecido, ensaio e método para condução de ensaio e composição farmacêutica | |
| CL2022001130A1 (es) | Moléculas de fusión del ecd de siglec-9 y métodos de uso de estas | |
| CL2022001035A1 (es) | Composiciones y métodos para minimizar la pérdida de proteínas a concentraciones de proteínas bajas | |
| BR112019010034A2 (pt) | fator viii alvejado de hemácia e método de uso do mesmo | |
| BR112016008086A2 (pt) | Glicoproteínas recombinantes e usos das mesmas | |
| BR112013011015A2 (pt) | formas sólidas de ácido (s)-2-amino-3-(4-(2-amino-6-((r)-1-(4-cloro-2-(3-metil-1h-pirazol-1-il)fenil)-2,2,2-trifluoroetóxi)pirimidin-4-il)fenil)propanoico | |
| CL2025003864A1 (es) | Proteínas de fusión de una o varias citocinas y sus usos. | |
| BR112022026974A2 (pt) | Proteínas de fusão estabilizadas de proteínas de pico de coronavírus | |
| BRPI1015190A8 (pt) | Processo para a sincronização das medidas obtidas, em um período dado, a partir de vários meios de aquisição de medidas de características ligadas às tensões suportadas por um pneumático equipando um veículo em circulação |